Xenon Pharmaceuticals Inc.

DB:XP0 Stock Report

Market Cap: €3.1b

Xenon Pharmaceuticals Management

Management criteria checks 2/4

Xenon Pharmaceuticals' CEO is Ian Mortimer, appointed in Mar 2018, has a tenure of 6.67 years. total yearly compensation is $10.12M, comprised of 6.6% salary and 93.4% bonuses, including company stock and options. directly owns 0.06% of the company’s shares, worth €1.86M. The average tenure of the management team and the board of directors is 4.3 years and 3.7 years respectively.

Key information

Ian Mortimer

Chief executive officer

US$10.1m

Total compensation

CEO salary percentage6.6%
CEO tenure6.7yrs
CEO ownership0.06%
Management average tenure4.3yrs
Board average tenure3.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ian Mortimer's remuneration changed compared to Xenon Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$213m

Jun 30 2024n/an/a

-US$199m

Mar 31 2024n/an/a

-US$189m

Dec 31 2023US$10mUS$666k

-US$182m

Sep 30 2023n/an/a

-US$176m

Jun 30 2023n/an/a

-US$165m

Mar 31 2023n/an/a

-US$148m

Dec 31 2022US$9mUS$595k

-US$126m

Sep 30 2022n/an/a

-US$113m

Jun 30 2022n/an/a

-US$91m

Mar 31 2022n/an/a

-US$83m

Dec 31 2021US$4mUS$524k

-US$81m

Sep 30 2021n/an/a

-US$66m

Jun 30 2021n/an/a

-US$59m

Mar 31 2021n/an/a

-US$37m

Dec 31 2020US$2mUS$462k

-US$29m

Sep 30 2020n/an/a

-US$28m

Jun 30 2020n/an/a

-US$28m

Mar 31 2020n/an/a

-US$38m

Dec 31 2019US$2mUS$421k

-US$42m

Sep 30 2019n/an/a

-US$39m

Jun 30 2019n/an/a

-US$44m

Mar 31 2019n/an/a

-US$42m

Dec 31 2018US$923kUS$342k

-US$34m

Sep 30 2018n/an/a

-US$34m

Jun 30 2018n/an/a

-US$27m

Mar 31 2018n/an/a

-US$27m

Dec 31 2017US$945kUS$312k

-US$31m

Compensation vs Market: Ian's total compensation ($USD10.12M) is above average for companies of similar size in the German market ($USD1.93M).

Compensation vs Earnings: Ian's compensation has increased whilst the company is unprofitable.

CEO

Ian Mortimer (48 yo)

6.7yrs

Tenure

US$10,117,829

Compensation

Mr. Ian C. Mortimer, M.B.A, C.P.A, C.M.A., has been the Chief Executive Officer and Director at Xenon Pharmaceuticals Inc. since June 03, 2021. He has been an Independent Director at Perimeter Medical Imag...

Leadership Team

NamePositionTenureCompensationOwnership
Ian Mortimer
President6.7yrsUS$10.12m0.060%
€ 1.9m
Sherry Aulin
Chief Financial Officer3.4yrsUS$3.52m0%
€ 0
Robin Sherrington
Executive Vice President of Strategy & Innovationno dataUS$2.37mno data
Christopher Von Seggern
Chief Commercial Officer4.3yrsUS$2.76m0.0053%
€ 163.6k
Christopher Kenney
Chief Medical Officer3.3yrsUS$3.58m0%
€ 0
Andrea DiFabio
Chief Legal Officer & Corporate Secretary2yrsUS$3.55mno data
Shelley McCloskey
Executive Vice President of Human Resources5.2yrsno datano data
James Empfield
Executive Vice President of Drug Discovery8.8yrsUS$545.00kno data
Sheila Grant
Executive Vice President of R&D Operations4.3yrsno datano data

4.3yrs

Average Tenure

54.5yo

Average Age

Experienced Management: XP0's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ian Mortimer
President3.4yrsUS$10.12m0.060%
€ 1.9m
Justin Gover
Independent Director1.3yrsUS$770.91kno data
Gary Patou
Independent Director20.8yrsUS$560.09k0.037%
€ 1.2m
C. Machado
Independent Director4yrsUS$559.58kno data
Steven Gannon
Independent Director9.5yrsUS$561.42k0.0026%
€ 81.7k
Dawn Svoronos
Independent Chairman8.2yrsUS$588.37k0.033%
€ 1.0m
Gillian Cannon
Independent Director1.3yrsUS$770.91kno data
Elizabeth Garofalo
Independent Director3.4yrsUS$548.57kno data

3.7yrs

Average Tenure

61.5yo

Average Age

Experienced Board: XP0's board of directors are considered experienced (3.7 years average tenure).